Subscribe to Entrepreneur for $5
Subscribe

Why CRISPR Therapeutics (CRSP) Stock is Falling Today

Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?

By
This story originally appeared on Zacks

Shares of leading gene editing company CRISPR Therapeutics CRSP are sliding on Friday, down about 4.8% in midday trading Friday and on its way to a losing week. CRSP has fallen over 11% week-to-date so far. CRISPR’s recent downward move also follows a weak performance in September when the stock fell 10.4%.

- Zacks

What’s behind the slump?

There doesn’t seem to be any business or operations-specific news that’s driving CRSP down, but rather investors are continuing to cash out of speculative and high-growth plays. Growth stocks were hit particularly hard last month as inflation worries, rising bond yields, and other macroeconomic factors weighed on markets.

Despite the recent bout of volatility, CRISPR Therapeutics and gene-editing technology still holds a ton of promise. But current and potential investors should be cautious; CRSP is a high-risk, high-reward stock and there could be some major up or down swings on the horizon.



Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research